Argenx Se (ARGX) Total Current Liabilities (2015 - 2025)
Argenx Se (ARGX) posted Total Current Liabilities of $1.3 billion for Q4 2025, down 99.87% on a QoQ basis from $1041.9 billion in Q2 2025, and up 97.07% year-over-year from $669.9 million in Q4 2024.
Argenx Se (ARGX) Total Current Liabilities (2015 - 2025) Analysis & Trends
Argenx Se's Total Current Liabilities history runs 11 years deep, the most recent figure standing at $1.3 billion for Q4 2025.
- Quarterly Total Current Liabilities rose 97.07% year-over-year to $1.3 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 billion (up 97.07% YoY) and the FY2025 annual result came in at $1.3 billion, up 97.07% from the prior year.
- Total Current Liabilities was $1.3 billion for Q4 2025 at Argenx Se, down from $1041.9 billion in the prior quarter.
- Across five years, Total Current Liabilities topped out at $1041.9 billion in Q2 2025 and bottomed at $244.0 million in Q2 2021.
- A 5-year average of $104.6 billion and a median of $370.4 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Current Liabilities declined 5.62% — and 2025, when it jumped 208435.53%.
- Argenx Se's Total Current Liabilities stood at $301.2 million in 2021, then advanced by 0.34% to $302.3 million in 2022, then surged by 39.94% to $423.0 million in 2023, then soared by 58.38% to $669.9 million in 2024, then jumped by 97.07% to $1.3 billion in 2025.
- Business Quant data shows ARGX's Total Current Liabilities at $1.3 billion in Q4 2025, $1041.9 billion in Q2 2025, and $669.9 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 66.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 13.42 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.81 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 289.60 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 1.35 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.32 Bn |
| Jun 30, 2025 | 1,041.90 Bn |
| Dec 31, 2024 | 669.92 Mn |
| Jun 30, 2024 | 499.63 Mn |
| Dec 31, 2023 | 422.99 Mn |
| Jun 30, 2023 | 317.79 Mn |
| Dec 31, 2022 | 302.28 Mn |
| Jun 30, 2022 | 264.60 Mn |
| Dec 31, 2021 | 301.24 Mn |
| Jun 30, 2021 | 244.04 Mn |
| Dec 31, 2020 | 319.17 Mn |
| Jun 30, 2020 | 217.90 Mn |
| Dec 31, 2019 | 177.05 Mn |
| Jun 30, 2019 | 115.05 Mn |
| Dec 31, 2018 | 45.72 Mn |
| Jun 30, 2018 | 32.26 Mn |
| Dec 31, 2017 | 28.87 Mn |
| Jun 30, 2017 | 38.74 Mn |
| Dec 31, 2016 | 34.90 Mn |
| Dec 31, 2015 | 9.52 Mn |